Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BTAI 
BioXcel Therapeutics Inc (BTAI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/04/2025: BTAI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $16.75
1 Year Target Price $16.75
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -95.02% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/04/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 41.77M USD | Price to earnings Ratio - | 1Y Target Price 16.75 |
Price to earnings Ratio - | 1Y Target Price 16.75 | ||
Volume (30-day avg) 3 | Beta 0.22 | 52 Weeks Range 1.17 - 9.26 | Updated Date 12/3/2025 |
52 Weeks Range 1.17 - 9.26 | Updated Date 12/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.44 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -1.34 | Actual -2.18 |
Profitability
Profit Margin - | Operating Margin (TTM) -14320.41% |
Management Effectiveness
Return on Assets (TTM) -67.31% | Return on Equity (TTM) -1766.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 114005948 | Price to Sales(TTM) 55.55 |
Enterprise Value 114005948 | Price to Sales(TTM) 55.55 | ||
Enterprise Value to Revenue 151.6 | Enterprise Value to EBITDA -0.75 | Shares Outstanding 21869491 | Shares Floating 21318599 |
Shares Outstanding 21869491 | Shares Floating 21318599 | ||
Percent Insiders 4.21 | Percent Institutions 12.1 |
Upturn AI SWOT
BioXcel Therapeutics Inc
Company Overview
History and Background
BioXcel Therapeutics, Inc. was founded in 2007. It focuses on utilizing artificial intelligence to identify drug candidates in neuroscience and immuno-oncology. Initially focused on drug repurposing, it has evolved to develop novel therapies.
Core Business Areas
- Neuroscience: Development and commercialization of therapies for acute agitation and other neuropsychiatric disorders. This segment focuses primarily on BXCL501 (dexmedetomidine sublingual film), marketed as Igalmi.
- Immuno-oncology: Research and development of therapies to treat cancer. This segment is in earlier stages, involving pre-clinical and clinical trials.
Leadership and Structure
The company is led by a management team with expertise in drug development and commercialization. The organizational structure includes departments focused on R&D, clinical trials, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Igalmi (dexmedetomidine sublingual film): Igalmi is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. As a relatively new product, market share data is still developing. Competitors include traditional antipsychotics like haloperidol and lorazepam, as well as other atypical antipsychotics. Data on revenue from this product is still emerging, as the drug has just been launched.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. It is characterized by high R&D costs, lengthy approval processes, and patent protection. The neuroscience market, specifically for agitation treatments, is growing due to increasing awareness and diagnosis of mental health conditions.
Positioning
BioXcel Therapeutics is positioned as an innovator in the treatment of acute agitation using AI-driven drug development. Its competitive advantage lies in its novel formulation and route of administration (sublingual film) for dexmedetomidine.
Total Addressable Market (TAM)
The TAM for acute agitation treatment is estimated to be in the billions of dollars, encompassing hospital settings, psychiatric facilities, and potentially outpatient use. BioXcel is targeting a portion of this TAM with Igalmi, focusing on rapid onset and ease of administration.
Upturn SWOT Analysis
Strengths
- Novel AI-driven drug discovery platform
- FDA-approved product (Igalmi)
- Sublingual formulation offers rapid onset
- Strong intellectual property portfolio
Weaknesses
- Limited commercialization experience
- Dependence on single approved product (Igalmi)
- High cash burn rate
- Need for further clinical data to support broader use of Igalmi
Opportunities
- Expansion of Igalmi's label to include other indications
- Partnerships with pharmaceutical companies for commercialization
- Development of new drug candidates using AI platform
- Market growth in mental health treatments
Threats
- Competition from established antipsychotics
- Regulatory hurdles and delays
- Patent challenges
- Unfavorable reimbursement policies
Competitors and Market Share
Key Competitors
- LLY
- ABBV
- VTRS
Competitive Landscape
BioXcel Therapeutics' advantage lies in its novel mechanism of action for acute agitation. However, it faces competition from well-established pharmaceutical companies with broader product portfolios and greater resources. BioXcel is carving a niche with its AI platform to drive efficiency in the traditional drug discovery efforts.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is marked by the transition from R&D to commercialization with the approval of Igalmi. Revenue growth is expected to increase significantly in the coming years.
Future Projections: Future growth is dependent on the successful commercialization of Igalmi and the development of new drug candidates. Analyst estimates vary widely, reflecting the uncertainty inherent in biotech investments.
Recent Initiatives: Recent initiatives include expanding the commercial reach of Igalmi, conducting post-marketing studies, and advancing the pipeline of immuno-oncology candidates.
Summary
BioXcel Therapeutics is a development-stage pharmaceutical company with a promising AI-driven drug discovery platform. Its success hinges on the commercial uptake of Igalmi. While its innovative approach and FDA approval are strengths, high cash burn and dependence on a single product present risks. The company must expand its pipeline and manage its finances carefully to achieve long-term sustainability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Press Releases
- Third-party Pharmaceutical Databases
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioXcel Therapeutics Inc
Exchange NASDAQ | Headquaters New Haven, CT, United States | ||
IPO Launch date 2018-03-08 | Founder, CEO, President, & Director Dr. Vimal D. Mehta Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | |
Full time employees 37 | |||
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.